• Kabir Nath

    President & CEO, Otsuka North America Pharmaceutical Business

    Kabir Nath

    President & CEO, Otsuka North America Pharmaceutical Business

    Kabir is a senior commercial leader with more than 25 years of broad international biopharma and devices experience who has shaped strategy and delivered results in complex, challenging business environments at country, regional and global levels. He has lived and worked in the U.K., France, Spain, India, Singapore, China and the US. Kabir joined Otsuka to head the North American pharmaceutical business in March 2016, with direct responsibility for Otsuka America Pharmaceuticals, Inc., Avanir and Otsuka Canada. Before joining Otsuka, Kabir spent 13 years in leadership roles at Bristol Myers Squibb. Most recently he was Senior Vice President, Virology, Transplant & Optimized Brands, responsible for the commercialization of a significant portfolio – including drugs for HIV, hepatitis B and hepatitis C and immunosuppression in the USA. Previously he was Senior Vice President, Global Commercialization Virology & Neuroscience, leading global strategy for these two disease areas. In addition he served as interim head of Emerging Markets for much of 2012. Kabir joined BMS in Singapore in 2003 as vice president for South East Asia/Taiwan/HK and moved to Shanghai in 2005 as president of BMS China. In 2008, Kabir was appointed president, Asia Pacific Medicines, with responsibility for all commercial operations in 13 countries. Prior to joining BMS, Kabir spent 11 years at Smith & Nephew, the medical technology company, in senior operational and strategic roles in the U.K., Europe and Asia. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.
  • Louis Allesandrine

    VP, Oncology and Renal Sales & Marketing

    Louis Allesandrine

    VP, Oncology and Renal Sales & Marketing

    "At Otsuka, we drive innovation and creativity by following the company philosophy; Taking the Road Less Traveled. It helps us address unmet needs of patients, their caregivers, and healthcare professionals, keeping us focused on doing our part to provide better health worldwide."

    As Vice President of Oncology and Renal Sales & Marketing at Otsuka America Pharmaceutical, Inc. (OAPI) I am responsible for leading the strategic development and execution of our U.S.-based commercial oncology renal businesses. This includes the co-promotion of SPRYCEL® (dasatinib) with BMS and our clinical stage collaborations with Astex Pharmaceuticals, a member of The Otsuka Group. Our goal is to develop and bring novel cancer therapeutics to market; meeting the needs of patients, their care givers and healthcare professionals. I joined OAPI in 2017 after 25 years of commercial experience in the pharmaceutical industry. Prior to joining OAPI, I served 6 years as Vice President, Oncology Marketing at Boehringer Ingelheim. Earlier in my career I held a series of leadership positions in sales and marketing focused in the areas of oncology and urology specialty care. I received an M.B.A. degree from Quinnipiac University.
  • Kevin Donovan
    Kevin B. Donovan

    M.S.
    Sr. VP, Otsuka-People, Business Services & Communications

    Kevin Donovan

    Kevin B. Donovan

    M.S.
    Sr. VP, Otsuka-People, Business Services & Communications

    “Otsuka-people dare to dream and we take the road less traveled to influence the future.”

    As the Senior Vice President of Otsuka-People, Business Services & Communications at Otsuka America Pharmaceutical, Inc., (OAPI) I have responsibility for overseeing all human resources functions for the U.S. business. Before joining Otsuka in 2009, I was Director, Human Resources, U.S. Field Sales, at AstraZeneca, supporting a sales force of approximately 6,000 people. At AstraZeneca, I also held positions of Director, Global Human Resources Strategy, in London and Director, Human Resources, U.S. Operations. Earlier, I spent eight years at Bristol-Myers Squibb (BMS) and DuPont Pharmaceuticals Co., which was acquired by BMS. I have a B.S. degree from the University of Delaware and a Master’s degree in Organization Dynamics from the University of Pennsylvania.
  • Jennifer McGee, Esq.

    J.D.
    Chief Compliance Officer, VP, Ethics & Compliance

    Jennifer McGee, Esq.

    J.D.
    Chief Compliance Officer, VP, Ethics & Compliance

    As Chief Compliance Officer, I am responsible for ensuring that Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. maintain a robust and effective ethics and compliance program.  I joined Otsuka in January 2011, as Senior Compliance Counsel, and assumed the responsibilities of Chief Compliance Officer in May 2015.  Prior to joining Otsuka, I worked as a litigator at a multinational law firm, focusing on defending pharmaceutical and medical device manufacturers in government investigations and lawsuits.  I also served in the United States Army for more than 13 years, trying more than 70 felony criminal trials, and remain in the United States Army Reserves.  I earned a B.A. degree from St. Lawrence University and a Juris Doctor degree from University of Maryland School of Law.
  • Innes Meldrum

    VP, CNS Marketing and Sales

    Innes Meldrum

    VP, CNS Marketing and Sales

    "My motivation for working at Otsuka is that most companies talk about innovation but at Otsuka it's part of the DNA. One of my favorite quotes is that "the definition of insanity is doing the same thing and expecting different results" by Albert Einstein. I believe strongly that the essence of marketing is effectively differentiating vs the competition and to do this requires adopting new approaches that challenge conventional thinking and by implication the status quo. Otsuka provides an environment that actively encourages this."

    As Vice President of the CNS & Cardio-Renal Marketing organization at Otsuka America Pharmaceutical, Inc. (OAPI) I am responsible for leading our Marketing and Sales teams to create, execute, and innovative differentiated marketing strategies and tactics. I also have responsibility for commercialization of our CNS & Cardio-Renal pipelines. I have more than 20 years of experience in executive strategic, marketing, sales and business operations in both the pharmaceutical and technology industries. I joined Otsuka in 2017. Prior to joining Otsuka, I spent 3 years at Orexo, as Head of US Sales and Marketing, focused on the Opioid Addiction market. Before this I worked in a variety of Global and US roles with Novartis and most recently was Head of Sales and Marketing of the U.S. NeuroPsychiatry business. Prior to this I spent 10 years working in the tech. industry with Nortel Networks, HP and Agilent Technologies focussed on developing solutions for the Wireless Telecomms industry. I earned a B.Eng. in Electrical and Electronic Engineering from Strathclyde University in Glasgow, Scotland.
  • Mary Michael

    VP, Congress Stakeholder Management & Patient Advocacy

    Mary Michael

    VP, Congress Stakeholder Management & Patient Advocacy

    “Otsuka embraces innovative thinking. It is not our slogan, but our calling to create patient-centered solutions for some of the toughest diseases in CNS, oncology, and more. We don’t shy away from problems. We embrace them to find solutions.”

    As Vice President of Patient Advocacy and Stakeholder Management at Otsuka America Pharmaceutical, Inc. (OAPI), I have the unique opportunity to work with trailblazing leaders both inside and outside the clinic walls to create innovative patient-centered solutions. It is my responsibility to understand how the world is changing across multiple disease categories, and I pull together the thoughts, ideas, and research from a global array of key opinion leaders, patient advocates, technologists, caregivers, and more to incubate novel business solutions. I am able to bring innovation to Otsuka by engaging with stakeholders from the world’s most prestigious medical centers to local advocacy chapters. Before coming to Otsuka, I spent nine years with Wyeth Pharmaceuticals in Opinion Leader and Advocacy Relations, where I developed and executed our Global Opinion Leader business strategies across the Specialty products portfolio. Prior to Wyeth, I was at Bristol-Myers Squibb for 13 years, in a variety of positions. At Otsuka, I have spearheaded the launch of the Global Council on Alzheimer’s Disease (GCAD), a collection of preeminent experts who influence the Alzheimer’s space, including science, medicine, technology, policy, advocacy, and caregiving. Through GCAD, I have jumpstarted technological innovation, framed a patient navigation model for Alzheimer’s, and helped improve communications between families and healthcare providers. I am a graduate of Virginia Tech as well as Singularity University.
  • Ron Newbold

    PhD, MBA
    Sr. VP, Business Development & Alliances

    Ron Newbold

    PhD, MBA
    Sr. VP, Business Development & Alliances

    “There is a unique opportunity within Otsuka to think differently. We have the freedom to go beyond our roles to contribute, to innovate, and produce outcomes that impact our overall mission. We are encouraged to challenge the status quo. And that is refreshing.”

    As Senior Vice President, Business Development & Alliances, I focus on bringing together resources from both Otsuka and Avanir to create a highly effective business development function. I work closely with our U.S. leadership team, and senior leadership in both Europe and Japan to develop and execute on a comprehensive business development strategy. With an initial background in medicinal chemistry, I bring more than 20 years of experience in business development roles at several biotech and pharmaceutical companies. Throughout my career, I have managed all functional areas of business development. Prior to Otsuka, I served as Vice President, External Research and Development Innovation at Pfizer, Inc. In that role, I was responsible for leading Pfizer’s global scouting and early-investment activities with academic partners, venture capital firms, and biotech companies. I also built and ran the Pfizer Seed Fund, which supported investments in new companies as a channel to Pfizer’s later-stage Corporate Venture Fund. I also led the Emerging Science Fund – established to encourage Pfizer’s R&D groups to forge collaborations with academia and biotech companies, supporting >135 collaborations during my tenure. I have a Bachelor of Science degree in Chemistry from Union College, a Ph.D. in Synthetic Organic Chemistry from the University of Rochester, and completed my postdoctoral fellowship at Harvard University. I also hold an MBA in Management and Finance from Columbia University.
  • Edward Stelmakh
    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    Edward Stelmakh

    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    "My primary motivation for working at Otsuka is to help define and execute on our corporate strategic goals as we deal with continuously changing landscape of internal and external challenges and opportunities. I have a real passion for driving positive change and working in an environment where one can make significant impact across a broad spectrum of areas. I truly believe that the only constant in life is change and Otsuka’s success as an organization is hinged upon its willingness and ability to embrace changes occurring in the pharmaceutical industry landscape."

    As Senior Vice President and CFO at Otsuka America Pharmaceutical, Inc. (OAPI), I am responsible for all areas of Finance supporting the U.S. business, including Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).  In my current role, I oversee accounting, business support, financial planning and analysis, treasury, M&A, internal controls and tax functions.  In addition to Finance, I manage the established product portfolio, market access pricing support and strategic outsourcing functions.  Prior to joining Otsuka in 2015, I spent six years as Vice President, Finance, Clinical Development and Commercialization Services at Covance (a division of LabCorp), leading finance and commercial support functions of a global billion-dollar division with 5,000 employees worldwide. Prior to Covance, I held a variety of positions with growing responsibilities within Organon (Schering Plough), Mylan, Sanofi-Aventis and Johnson & Johnson. My background includes a broad spectrum of financial, commercial and operational leadership roles, including eight years of international assignments in the Netherlands and Russia.  I received a B.S. in Finance from Towson University, and an M.B.A. from University of Baltimore. I am also a Certified Public Accountant (New Jersey) and a Certified Management Accountant. I am an active member of the Princeton community and currently serve as Treasurer of the Arts Council of Princeton.
  • Steven Weis
    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    Steven Weis

    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    "Otsuka is committed to conducting business with integrity at all times. We strive to be creative and innovative without ever losing sight of the laws and regulations that govern our industry and the trust that doctors, patients, and their families have placed in us."

    As Vice President and General Counsel at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I lead the Legal Affairs department, which provides legal counsel and support to OPDC and its sister company Otsuka America Pharmaceutical, Inc. (OAPI). Earlier at Otsuka, I held various leadership positions in Legal Affairs and Human Resources, such as Senior Director & Corporate Counsel, Senior Corporate Attorney, and Senior Human Resources Business Partner. I joined Otsuka in 2001 after a career in business that included overseeing human resources functions at a major commercial printing company and two technology companies. I earned a B.A. degree and a Juris Doctor degree from The George Washington University.
  • Andrew Wright
    Andrew Wright

    Vice President, Digital Medicine and Head of Expanded Collaboration Business Unit Company

    Andrew Wright

    Andrew Wright

    Vice President, Digital Medicine and Head of Expanded Collaboration Business Unit Company

    “Our journey with digital medicine was inspired by the late President of Otsuka, Dr. Taro Iwamoto. He drove the value of innovation. He challenged us to think differently about solving unmet healthcare needs through alliances and technology. We are working to fulfill this vision by going beyond the pill.”

    As Vice President of Digital Medicines, at Otsuka America Pharmaceutical, Inc. (OAPI) I am responsible for leading the commercialization of wearable computing and digital products. Our goal is to enable improved patient medication adherence and better-informed physician decision-making to tailor treatment to the patient’s needs. I have more than 25 years of U.S. and Global experience in commercial leadership roles in the pharmaceutical industry. Earlier, I worked at Novartis as Head, HCP Digital/Multi-Channel Marketing, Global Commercialization, and was responsible for identifying and developing digital and multi-channel solutions that enhanced customer engagement. Prior to that, as Executive Director, Insights & Innovation, I led and developed a team responsible for customer/brand insights and innovation across the U.S. pharmaceutical business. I also held senior marketing and sales roles for in-line and launch brands at Novartis, producing consistently strong results. At Pharmacia, I led the launch of a major product in 11 markets across Europe. My Bachelor of Science degree is in Business Administration from Crewe and Alsager College.
  • William Carson
    William H. Carson

    A.B., M.D.
    President & CEO, OPDC

    William Carson

    William H. Carson

    A.B., M.D.
    President & CEO, OPDC

    “Otsuka’s relentless pursuit of innovative solutions that address unmet patient needs while leveraging cutting edge technology enables us to deliver on our mission – developing new products for better health worldwide. The challenges in mental health and oncology are extensive and complex, but Otsuka-people are determined and committed to developing solutions. We have a robust and diverse pipeline that prepares us to meet the needs of today, and shape the world of tomorrow.”

    I am the President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). My responsibilities include leading the team that develops new products and brings them to market, as well as creating strategic plans for the company’s product portfolio to ensure development programs meet quality and safety standards required by medical and regulatory agencies. Since my appointment in 2010, I have led the development efforts of compounds in neuroscience, cardio-renal, and oncology, and was instrumental in the development and registration of ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension. I also helped guide the development and registration of SAMSCA® (tolvaptan), marking the first time Otsuka successfully developed and commercialized a product entirely on its own in the U.S. I joined Otsuka in 2002 as a board-certified psychiatrist and served as OPDC’s Senior Vice President, Global Clinical Development, overseeing the development of Otsuka-discovered compounds. During my career at Otsuka—and earlier at Bristol-Myers Squibb (BMS)—I was one of the key drivers in the development and commercialization of ABILIFY® (aripiprazole), which Otsuka marketed in collaboration with BMS. I received an A.B. degree in history and science from Harvard University and an M.D. degree from Case Western Reserve University.
  • Debbie Daniel
    Debbie Daniel

    M.B.A.
    VP, Corporate Projects

    Debbie Daniel

    Debbie Daniel

    M.B.A.
    VP, Corporate Projects

    "Throughout my tenure at the organization, I’ve been inspired by Otsuka’s environment of dynamic challenges and opportunities. The organization is constantly evolving and changing and you just never know what you will be challenged to work on next."

    As Vice President of Corporate Projects for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) I manage the company’s Operating Committee, leading initiatives such as Global Pharmacovigilance Reform and Oncology Alliance Management, as well as expanding the scope of corporate projects. Since joining Otsuka in August 1997 as a Program Manager for ABILIFY® (aripiprazole), I have also been responsible for the project management of development and commercialization activities for various products as well as the managerial oversight of the quality management, project management and corporate management departments. Prior to joining Otsuka, I held roles in Clinical Development and Central Contracts and Grants at the R.W. Johnson Pharmaceutical Research Institute. My career in health care began as a medical technologist at Duke University Medical Center. I am certified in Medical Technology through the American Society of Clinical Pathologists and am a member of the Drug Information Association. I received a B.S. degree in Medical Technology from the University of North Carolina at Chapel Hill and an M.B.A. from Penn State University with an emphasis in Marketing.
  • Timothy Peters-Strickland

    M.D.
    VP, Global Clinical Development, CNS and Digital Medicine

    Timothy Peters-Strickland

    M.D.
    VP, Global Clinical Development, CNS and Digital Medicine

    “Over the last six years, I have become part of the fabric of Otsuka by living the culture day to day. We collaborate to turn drug development challenges into practical solutions that will help and support patients with serious mental illnesses worldwide. At Otsuka, we know we can achieve anything together.”

    As Vice President, Global Clinical Development, CNS and Digital Medicine at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Timothy has responsibility for overseeing all development activities across CNS and Digital Medicine.  Timothy joined Otsuka in 2012 and is an effective leader, successfully directing several CNS clinical development programs, including ABILIFY MAINTENA® (aripiprazole) and ABILIFY MYCITE® (aripiprazole tablet with sensor). Most recently, Timothy served as the clinical lead for the ABILIFY MYCITE program, leading the cross-functional and alliance teams in the development of a first of its kind product for which there was no clinical and regulatory precedent. Timothy has also contributed to numerous medical journals, manages the Otsuka CNS Pharmaceutical Medicine Fellowship program, and speaks at various industry conferences and other events on a regular basis. Prior to joining Otsuka, Timothy was Medical Director, Global Clinical Practice for 3.5 years at Covance, Inc. and was in private practice for 13 years prior to joining the pharmaceutical industry.  Timothy received a B.S. degree in Biochemistry from Florida State University, and a M.D. from the University of Florida College of Medicine.  He completed his psychiatric residency at the University of Southern California where he was chief resident his final year.   
  • Nick Kurahashi

    M.S.
    VP, Global CNS Business

    Nick Kurahashi

    M.S.
    VP, Global CNS Business

    I am Vice President of the Global CNS Business for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). I am responsible for Alliance Management with companies with which we have formed alliances, as well as development of global clinical and commercialization strategy for CNS and digital innovation products. My career at Otsuka began in 1988, as a researcher and organic chemist for psychiatry disorders in the CNS group in Japan and has steadily progressed to the clinical and commercial side, as well as taking on global roles. In 1996, I became the Product Development Coordinator responsible for the development and coordination of the global clinical and commercialization plan for the anti-platelet agent. Starting in 2000, I was the International Manager of ABILIFY® (aripiprazole), Otsuka America Pharmaceutical, Inc. I managed the coordination between the US, EU, Japan and Asia, as well as Alliance Management. By 2003, I became the ABILIFY Product Marketing Manager leading the brand in Japan, until beginning my current role in 2010. I had the unique opportunity and honor of contributing to the research and development as well as commercialization of ABILIFY. During my tenure at Otsuka global mobility has afforded us an opportunity to exchange knowledge with our peers as we bring different perspectives and problem-solving abilities to the conversation based on our professional backgrounds.  Today, I am really passionate about the future of Otsuka and how our company can leverage technology and digital innovation to advance healthcare and help make the world a healthier place for all.  Prior to joining Otsuka, I received my Master of Science for Pharmacy from Gifu Pharmaceutical University. 
  • Robert McQuade
    Robert McQuade

    Ph.D.
    Executive VP & Chief Strategic Officer

    smaller image of bob mcquade

    Robert McQuade

    Ph.D.
    Executive VP & Chief Strategic Officer

    Otsuka is not right for everyone. It is a dynamic environment for those who wish to be challenged and engaged every day. We are focused on bringing important new drugs and innovations to patients, especially for those with serious mental illness. This has been my personal goal throughout my career and through Otsuka I believe that I have in fact made a difference in the lives of these patients.

    As Executive Vice President & Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I am responsible for coordinating the development strategy for our compounds across their life cycle.   I have more than 30 years of experience in the discovery, development, and marketing of drugs for the treatment of mental illness. My career started as a post-doctoral fellow in central nervous system (CNS) research at Schering-Plough Pharmaceuticals and gradually advanced to Associate Director of CNS Pharmacology.  In this role, I supervised the biochemical pharmacology group in their efforts to discover new drugs for mental illness, including schizophrenia and Alzheimer’s disease. I next joined the Global Medical Affairs team at Bristol-Myers Squibb (BMS). While at BMS, I was responsible for various products, including psychiatric treatments for generalized anxiety disorder and major depressive disorder.  More importantly, I was part of the team that helped form the alliance between BMS and Otsuka for the development and commercialization of aripiprazole. It was only natural that I ultimately joined Otsuka in 2004 to oversee global medical affairs for ABILIFY® (aripiprazole).  My roles have grown over the years and now I am responsible for the global development strategy for Otsuka’s compounds in the CNS, cardio-renal and oncology therapeutic areas. In addition, I am involved in many of Otsuka’s external collaborations and business development initiatives. I received a B.S. degree from Davidson College and a Ph.D. from the University of North Carolina-Chapel Hill.
  • Deborah Proffit
    Deborah Profit

    Ph.D.
    VP, Applied Innovation and Process Improvement

    Deborah Proffit

    Deborah Profit

    Ph.D.
    VP, Applied Innovation and Process Improvement

    “The knowledge sharing facilitated through our collaborations with some of the most prestigious institutions of higher learning in the country has been unprecedented. These collaborations have challenged us to think differently and evaluate how we can improve our own processes and introduce new methodologies in order to achieve the best possible outcomes.”

    As the Leader of Applied Innovation and Process Improvement at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) I am responsible for both the R&D and Commercial arms of the Otsuka IT organization. Since 2001, I have driven strategy and solutions by collaborating with functional departments, key stakeholders and external parties to increase Otsuka’s probability of clinical, regulatory and technical success. I am responsible for facilitating creative technical solutions across clinical development and commercial teams, coordinating engagements with external innovation companies/consultancies, and actively leading cross-functional pilots, prototypes and enterprise wide IT solutions. In addition, I have a key role in transitioning various pilots and prototypes to full-scale projects to leverage solutions that complement the business portfolio to include digital medicine, digital health and big data platforms. Prior to joining Otsuka Information Technology, key roles within the organization included Director, Corporate Projects for over five years and Associate Director of Clinical Operations for nine years. Before 2001, I spent over seven years as Director, Project Management at a top tier global clinical research organization (CRO). I have undergraduate degrees in nursing and psychology, a Master of Science in Regulatory Affairs - Drugs, Biologics and Medical Device, and a Doctorate in Leadership Studies with a concentration in Innovation and Creativity.
  • Mirza Rahman
    Mirza Rahman

    M.D., M.P.H., FAAFP, FACPM.
    Sr. VP, Clinical Safety & Pharmacovigilance, and Global Head of Pharmacovigilance

    Mirza Rahman

    Mirza Rahman

    M.D., M.P.H., FAAFP, FACPM.
    Sr. VP, Clinical Safety & Pharmacovigilance, and Global Head of Pharmacovigilance

    "At Otsuka, we recognize that drug safety is everyone’s business, not just the responsibility of the people working in Global Pharmacovigilance (GPV) and even as we seek to create new products for better health worldwide, all of us at Otsuka are focused on creating a world-class drug-safety organization, where patient safety is our highest priority."

    I am Senior Vice President, Clinical Safety & Pharmacovigilance, and the Global Head of Pharmacovigilance at Otsuka Pharmaceutical Development & Commercialization (OPDC), Inc. Shortly after joining Otsuka in 2013, I led the Otsuka Global Pharmacovigilance Reform Initiative, and currently lead all of Otsuka's pharmacovigilance operations globally. Additionally, I have been responsible for Global Medical Affairs activities at OPDC. I joined Otsuka from Merck Research Laboratories, where I was an Executive Director in the Clinical Risk Management/Global Safety department. There, I led a team that performed global pharmacovigilance and risk management activities for more than 425 Merck products. Prior to this, I was a Worldwide Vice President, Health Economics & Reimbursement at Ortho-Clinical Diagnostics, Johnson & Johnson. I earned an M.P.H. from Columbia University, an M.D. degree from the Stony Brook School of Medicine, and a B.S. degree from the Sophie Davis School of Biomedical Education at City College of the City University of New York. I am a Fellow of both the American Academy of Family Physicians (AAFP) and the American College of Preventive Medicine (ACPM), which in 2014 bestowed upon me their highest honor, the ACPM Distinguished Service Award.
  • John Sokol

    M.S.
    VP, Technical Operations

    John Sokol

    M.S.
    VP, Technical Operations

    “There are limitless opportunities at Otsuka to learn and to grow. It’s the Jissho culture. We push people to try new things and learn new areas of responsibilities, and then reward them when they succeed. I experienced this first-hand.”

    As Vice President of Technical Operations at Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC), I am responsible for pharmaceutical and medical device product development, global clinical supplies, and product supply for the US and international markets.   I joined Otsuka in 2011 as the Director of Packaging and Device Technology and helped launch the company's first combination product,  ABILIFY MAINTENA® (aripiprazole). Prior to joining Otsuka, I spent 16 years at Bristol-Myers Squibb, most recently as Associate Director, Package Development. My team delivered high-quality, cost-effective packaging solutions for oncology, cardiovascular, metabolic, and virology products globally.  I previously had similar responsibilities at Warner-Lambert and Block Drug Company. I earned a B.S. in Packaging Engineering from Rutgers University and an M.S. in Engineering Management from the New Jersey Institute of Technology. 
  • Henrietta Ukwu
    Henrietta Ukwu

    M.D., FACP., FRAPS.
    Sr. VP & Global Head, Global Quality and Global Regulatory Affairs

    Henrietta Ukwu

    Henrietta Ukwu

    M.D., FACP., FRAPS.
    Sr. VP & Global Head, Global Quality and Global Regulatory Affairs

    "At Otsuka, there are no boundaries to aspirations, achievements and appetite for innovation to drive health care solutions and make a difference to humanity."

    As Senior Vice President and Global Head of Global Quality and Global Regulatory Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I have responsibility for leading the global regulatory team, overseeing successful execution of regulatory activities and professional development of the team. My 23 years of professional global regulatory experience includes contributing to over 20 original new drug and biologics products development and approvals; enriching the regulatory profession through publications, including authoring the Global Regulatory Systems textbook and teaching and mentoring many successful regulatory professional protégés. My early regulatory career was spent at Merck, where I held increasingly senior regulatory leadership positions. At Wyeth Pharmaceuticals, I oversaw all therapeutic areas across all regions including responsibility for WHO and developing world countries. I joined Otsuka in 2013 from Pharmaceutical Product Development, LLC, having served as Senior Vice President, Head, Global Regulatory Affairs. I am a Fellow of the American College of Physicians (FACP) and Fellow of the Regulatory Affairs Professionals Society (FRAPS) and have received many awards for contributions to medicine and the pharmaceutical industry. My medical and surgical degrees are from the University of Jos School of Medicine in Nigeria, and I completed a postgraduate Internal Medicine residency at Baptist Hospital, University of Tennessee. My fellowship in Infectious Diseases was completed at the Vanderbilt University Medical Center in Nashville, Tennessee.
  • Edward Stelmakh
    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    Edward Stelmakh

    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    "My primary motivation for working at Otsuka is to help define and execute on our corporate strategic goals as we deal with continuously changing landscape of internal and external challenges and opportunities. I have a real passion for driving positive change and working in an environment where one can make significant impact across a broad spectrum of areas. I truly believe that the only constant in life is change and Otsuka’s success as an organization is hinged upon its willingness and ability to embrace changes occurring in the pharmaceutical industry landscape."

    As Senior Vice President and CFO at Otsuka America Pharmaceutical, Inc. (OAPI), I am responsible for all areas of Finance supporting the U.S. business, including Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).  In my current role, I oversee accounting, business support, financial planning and analysis, treasury, M&A, internal controls and tax functions.  In addition to Finance, I manage the established product portfolio, market access pricing support and strategic outsourcing functions.  Prior to joining Otsuka in 2015, I spent six years as Vice President, Finance, Clinical Development and Commercialization Services at Covance (a division of LabCorp), leading finance and commercial support functions of a global billion-dollar division with 5,000 employees worldwide. Prior to Covance, I held a variety of positions with growing responsibilities within Organon (Schering Plough), Mylan, Sanofi-Aventis and Johnson & Johnson. My background includes a broad spectrum of financial, commercial and operational leadership roles, including eight years of international assignments in the Netherlands and Russia.  I received a B.S. in Finance from Towson University, and an M.B.A. from University of Baltimore. I am also a Certified Public Accountant (New Jersey) and a Certified Management Accountant. I am an active member of the Princeton community and currently serve as Treasurer of the Arts Council of Princeton.
  • Steven Weis
    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    Steven Weis

    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    "Otsuka is committed to conducting business with integrity at all times. We strive to be creative and innovative without ever losing sight of the laws and regulations that govern our industry and the trust that doctors, patients, and their families have placed in us."

    As Vice President and General Counsel at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I lead the Legal Affairs department, which provides legal counsel and support to OPDC and its sister company Otsuka America Pharmaceutical, Inc. (OAPI). Earlier at Otsuka, I held various leadership positions in Legal Affairs and Human Resources, such as Senior Director & Corporate Counsel, Senior Corporate Attorney, and Senior Human Resources Business Partner. I joined Otsuka in 2001 after a career in business that included overseeing human resources functions at a major commercial printing company and two technology companies. I earned a B.A. degree and a Juris Doctor degree from The George Washington University.

NEUROSCIENCE

Otsuka has been committed for more than 3 decades to developing novel drugs for neurological conditions.